ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.38
0.74%
US Tech 100
20,836.00
1.31%
S&P 500
5,930.85
1.09%
US Dollar vs CAD
1.43421
0.14%
Bitcoin
97,458.23
-0.31%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. iTeos Therapeutics Inc (ITOS) Share Price

iTeos Therapeutics Inc

iTeos Therapeutics Inc (ITOS)

NASDAQ
7.42
0.20
(2.77%)
Closed December 21 3:00PM
Delayed by 15 minutes
7.4501
0.0301
(0.41%)
After Hours: 6:35PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
7.4501
Bid
7.20
Ask
7.42
Volume
2,443,970
7.09 Day's Range 7.51
7.12 52 Week Range 18.75
Market Cap
272.181M
Previous Close
7.22
Open
7.17
Last Trade
100
@
7.4501
(formt)
Last Trade Time
Financial Volume
US$ 17,692,784
VWAP
7.2394
Average Volume (3m)
551,139
Shares Outstanding
36,533,918
Dividend Yield
-
PE Ratio
-2.40
Earnings Per Share (EPS)
-3.08
Revenue
12.6M
Net Profit
-112.64M

About iTeos Therapeutics Inc

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.iteostherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
-
iTeos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ITOS. The last closing price for iTeos Therapeutics was US$7.22. Over the last year, iTeos Therapeutics shares have traded in a share price range of US$ 7.12 to US$ 18.75.

iTeos Therapeutics currently has 36,533,918 shares outstanding. The market capitalization of iTeos Therapeutics is US$263.77 million. iTeos Therapeutics has a price to earnings ratio (PE ratio) of -2.40.

Ask ADVFN Intelligence (AI)

ITOS Latest News

More News

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts...

December 12 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

December 06 2024
Edgar (US Regulatory)

iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and...

November 26 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

November 19 2024
Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

November 19 2024
Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

November 18 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 12 2024
Edgar (US Regulatory)

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2...

November 12 2024
GlobeNewswire Inc.

Form 8-K - Current report

November 04 2024
Edgar (US Regulatory)

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

October 24 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3599-4.608194622287.817.967.124607967.52985978CS
4-0.6399-7.909765142158.098.737.124273498.07838973CS
12-2.7399-26.888125613310.1910.937.125511398.84510996CS
26-7.4299-49.932123655914.8818.137.1252654211.63695583CS
52-3.6099-32.639240506311.0618.757.1243374412.34782131CS
156-35.0599-82.474476593742.5152.437.1240703418.05304375CS
260-12.2499-62.182233502519.752.437.1236084320.50245532CS

ITOS - Frequently Asked Questions (FAQ)

What is the current iTeos Therapeutics share price?
The current share price of iTeos Therapeutics is US$ 7.4501
How many iTeos Therapeutics shares are in issue?
iTeos Therapeutics has 36,533,918 shares in issue
What is the market cap of iTeos Therapeutics?
The market capitalisation of iTeos Therapeutics is USD 263.77M
What is the 1 year trading range for iTeos Therapeutics share price?
iTeos Therapeutics has traded in the range of US$ 7.12 to US$ 18.75 during the past year
What is the PE ratio of iTeos Therapeutics?
The price to earnings ratio of iTeos Therapeutics is -2.4
What is the cash to sales ratio of iTeos Therapeutics?
The cash to sales ratio of iTeos Therapeutics is 21.47
What is the reporting currency for iTeos Therapeutics?
iTeos Therapeutics reports financial results in USD
What is the latest annual turnover for iTeos Therapeutics?
The latest annual turnover of iTeos Therapeutics is USD 12.6M
What is the latest annual profit for iTeos Therapeutics?
The latest annual profit of iTeos Therapeutics is USD -112.64M
What is the registered address of iTeos Therapeutics?
The registered address for iTeos Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the iTeos Therapeutics website address?
The website address for iTeos Therapeutics is www.iteostherapeutics.com
Which industry sector does iTeos Therapeutics operate in?
iTeos Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.32M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
305.1M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
292.16M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
287.21M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
277.63M

ITOS Discussion

View Posts
Monksdream Monksdream 2 months ago
ITOS under $10
👍️0
Monksdream Monksdream 3 months ago
ITOS needs to break $19
👍️0
Awl416 Awl416 7 months ago
iTeos Therapeutics Announces $120 Million Registered Direct Offering
👍️0
TonyJoe1957 TonyJoe1957 3 years ago
$14.41 EPS estimate for 3rd quarter posted today on TDAmeritrade.
👍️0
TonyJoe1957 TonyJoe1957 3 years ago
https://seekingalpha.com/article/4449555-iteos-therapeutics-my-calculations-suggest-q3-earnings-will-exceed-10-per-share
👍️0
TonyJoe1957 TonyJoe1957 3 years ago
Wow!
No one posting or interested in this stock?
👍️0
TonyJoe1957 TonyJoe1957 4 years ago
Note the intraday lows for the past 3 trading days. Program trading walking it down to $25.60, $25.30 and $25.25. Stay well. AJ
👍️0
TonyJoe1957 TonyJoe1957 4 years ago
I think we are trading below cash per share.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 4 years ago
ITOS $28.50 gonna be wild in little after $30
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 4 years ago
Itos will break $30 and game on,holding here
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 4 years ago
ITOS~~$28.11
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 4 years ago
ITOS~~MA200,@ $28.75,should break today here
👍️0
TonyJoe1957 TonyJoe1957 4 years ago
Bought 580 sh, so far.
5 analysts at 8:30A webcast.
All congratulated the firm on the deal.
I anticipate an easy double in the next few months with upgrades.
Look at the balance sheet.
Really, really big cash infusion.
AJ
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 4 years ago
ITOS~~bought 809 shares @$33pm,little high on spike ,but should go nicely up,crazy huge news
👍️0
$treet $inatra $treet $inatra 4 years ago
https://investors.iteostherapeutics.com/news-and-events/press-releases


👍️0

Your Recent History

NASDAQ
ITOS
iTeos Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads